L. Biernat

LDL CHOLESTEROL REDUCTION WITH BMS-962476, AN ADNECTIN INHIBITOR OF PCSK9: RESULTS OF A SINGLE ASCENDING DOSE STUDY

E. Stein, S. Kasichayanula, U. Arumugam, 2014 .

Pharmacokinetic Profile and Tolerability of Liposomal Bupivacaine Following a Repeated Dose via Local Subcutaneous Infiltration in Healthy Volunteers

D. Rice, J. Heil, L. Biernat, 2017, Clinical Drug Investigation.

Rapid and Robust Mobilization of CD34+ HSCs without G-CSF Following Administration of Mgta-145 Alone or in Combination with Plerixafor

Anthony E. Boitano, M. Cooke, J. Dipersio, 2019, Blood.

Drug-induced liver damage -- a three-year study of patients from one gastroenterological department.

M. Hartleb, L. Biernat, A. Kochel, 2002, Medical science monitor : international medical journal of experimental and clinical research.

A randomized, double-blind, placebo controlled, phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of LB-102, a selective dopamine D2/3/5-HT7 inhibitor

M. Hixon, A. Vaino, L. Biernat, 2022, Psychopharmacology.

Phase 1 Single (SAD) and Multiple Ascending Dose (MAD) Studies of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of FT-4202, an Allosteric Activator of Pyruvate Kinase-R, in Healthy and Sickle Cell Disease Subjects

M. Telen, P. Malik, A. Drake, 2019, Blood.

LOW DENSITY LIPOPROTEIN CHOLESTEROL REDUCTION AND SAFETY WITH LIB003, AN ANTI-PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 FUSION PROTEIN: RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE ASCENDING DOSE STUDY

E. Stein, Rong Zhou, T. Turner, 2019, Journal of the American College of Cardiology.